Close Menu

irritable bowel syndrome

Using transcriptomic, metabolomic, metagenomic, and other data types, a team identified purine metabolism as a potential target for intervention.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.

Under the agreement, Theradiag will promote, license, and distribute PredictImmune's PredictSure IBD test in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries. 

Life Genomics will distribute Luxia's 1test1 test in Sweden, Denmark, Finland, Iceland, and Norway. The test leverages sequencing technology to analyze the 16s RNA gene.

The company is working with partners to identify new biomarkers and treatments as well as to collect utility evidence for its current coaching model.

In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.

Research suggests gut microbe representation, abundance, and function may provide clues for diagnosing Crohn's disease, ulcerative colitis, and irritable bowel syndrome.

The company said its test is the first biomarker-based diagnostic for IBD that predicts long-term disease outcome in Crohn's disease and ulcerative colitis.

The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.

Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.

Pages

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.